Navigation Links
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Date:4/2/2009

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the expected timing of the start of clinical trials with MT203, and the potential uses of MT203 and our other product candidates. You are urged to consider statements that include the words "looking forward," "ongoing," "may," "will," "believes," "potential," "expected," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ende
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/18/2014)... medical-testing device is being prepped to enter the ... diagnosis of certain diseases in remote areas, thanks ... of investigations aboard the International Space Station on ... space-tested concept of capillary flow to diagnose infectious ... Kelso, Ph.D., a researcher at Northwestern University in ...
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... Solta Medical, Inc. (Nasdaq: SLTM ), ... announced that it has received regulatory clearance to market ... excited about the opportunity to market the premier non-invasive ... Republic of China," said Stephen J. Fanning, Chairman of ...
... ProMetic Life Sciences Inc. (TSX: PLI ... announces that it has retained the services of ... subsidiaries of Sumitomo Corporation ("Sumitomo") to advise ProMetic in ... Japanese market.In the course of ProMetic,s partnering activities several ...
... that can cause anal and cervical cancers, is associated with ... men who have sex with men (MSM), according to new ... journal AIDS , the findings are available now. ... , In previous studies, other sexually transmitted infections have been ...
... Wolff today assured Pennsylvanians that the 2009 H1N1 influenza strain ... anywhere in either the U.S. or Mexico, and that pork ... as the ,swine flu, many misconceptions relating to pigs have ... and living near or working on a hog farm is ...
... 30 The Alzheimer,s Association Minnesota-North Dakota in collaboration ... segment of The Alzheimer,s Project on May 12 at ... screening will be followed by a question-and-answer panel of ... for the disease, The Alzheimer,s Project shows there is ...
... Exforge HCT combines a proven calcium channel blocker, ... in one pill - In a clinical trial, ... and diastolic BP, compared to all dual combinations ... patients may need multiple medications to help control ...
Cached Medicine News:Health News:Solta Medical Receives Regulatory Approval to Market Thermage Systems in China 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 3Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 4Health News:Cancer-causing virus associated with higher risk of new HIV infection 2Health News:Pennsylvania Pork Products Safe During H1N1 Flu Outbreak, Says Ag Secretary 2Health News:The Alzheimer's Project HBO Documentary Puts Spotlight On Alzheimer's Disease; Premiere Screening at the Hennepin County Library in Downtown Minneapolis 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7
Iso-Electric Determination Kit; contains 1 bottle of 40 nm Naked Gold Iso-Electric Determination Kit to optimize gold conjugation of antibodies...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 50 OD...
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 12 OD...
Medicine Products: